Biomerica Posts $1.20 Per-Share Q1 Loss as Cash Crunch Deepens
BMRA sits 21% above its 52-week low of $1.45 on light trading volume (0.2× avg).
Summary
Biomerica reported a fiscal Q1 loss of $1.20 per share on roughly $1.3M of sales, following the 10-Q filed October 15 that showed the net loss widening to $1.23M and gross margin collapsing to 8.1%, with revenue dropping on lower clinical lab orders. The company carries a going-concern warning with only about $2.7M of cash, and it has stacked a $250M universal shelf on top of the September resale S-3, so further dilution is the base case. The per-share loss lands on a stock trading near $1.75 with a micro-cap valuation, meaning any additional share issuance is highly dilutive to existing holders. The August private placement at $1.60 and insider buys at that level are now underwater relative to the current price. Watch for a 424B prospectus supplement off the shelf, which would mark the next actual capital raise.
At the time of this announcement, BMRA was trading at $1.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.6M. The 52-week trading range was $1.45 to $3.21. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.